Table 2. Primary (cure rates) and secondary clinical endpoints (parasite and fever clearance) for all treatment groups.

		Arm
Characteristics	1	2	3	P value Arm1 vs Arm 2	P value Arm1+2 vs 3	P value Arm 1 vs Arm 2 vs Arm 3
Cure rate Day 28
No. of patients evaluable on Day 28	45	46	22
No. of cured patients	44	46	22	0.92	0.89	0.995
Cure rate % (95%CI)	97.8	100	100
	(87.8–99.8)	(91.1–100)	(83.4–100)
Treatment failure	1	0	0	1	1	0.596
Cure rate Day 42 (PCR-corrected)
No. of patients evaluable for study end point Day 42	42	44	20
No. of cured patients	41	43	20	0.89	0.92	1
Cure rate %(95%CI)	97.8	100	100
	(87.8–99.8)	(91.1–100)	(83.4–100)
Treatment failure	1	1	0	1	1	1
PCT, h
Median (IQR)	29.8	29.5	43.1
	(24.3–32.8)	(19.8–32.4)	(33.6–54.8)	0,327	<0.001	<0.001
PCT50
Median (IQR)	9.3	8.5	29.5	0.542	0.002	0.006
	(6.5–18.4)	(7.1–17.5)	(7.1–31.0)
PCT90
Median (IQR)	17.6	17.4	30.0	0.905	<0.001	0.003
	(8.9–19.7)	(8.3–19.5)	(18.2–31.6)
Parasite reduction ratio
Median (IQR) after 12h	0.93	0.78	70.37	0.610	<0.001	<0.001
	(0.0–2.98)	(0.0–3.08)	(5.71–187.84)
Median (IQR) after 24h	0.0	0.0	0.8	0.857	<0.001	<0.001
	(0.0–0.0)	(0.0–0.0)	(0.0–7.14)
Median (IQR) after 36h	0.0	0.0	0.0	1	0.019	0.062
	(0.0–0.0)	(0.0–0.0)	(0.0–0.57)
FCT, h
Median (IQR)	17.9	19.1	29.3
	(4.6–20.7)	(6.6–23.6)	(16.0–43.1)	0.263	0.001	0.003

NOTE: 95%CI, 95% confidence interval; PCT, parasite clearance time in hours; IQR, interquartile range; PCT50, time in hours to 50% clearance of parasite density; PCT90, time in hours to 90% clearance of parasite density.